[go: up one dir, main page]

FI951132L - Polyamidi-oligonukleotidijohdoksia, niiden valmistus ja niiden käyttö - Google Patents

Polyamidi-oligonukleotidijohdoksia, niiden valmistus ja niiden käyttö Download PDF

Info

Publication number
FI951132L
FI951132L FI951132A FI951132A FI951132L FI 951132 L FI951132 L FI 951132L FI 951132 A FI951132 A FI 951132A FI 951132 A FI951132 A FI 951132A FI 951132 L FI951132 L FI 951132L
Authority
FI
Finland
Prior art keywords
preparation
oligonucleotide derivatives
polyamide oligonucleotide
polyamide
derivatives
Prior art date
Application number
FI951132A
Other languages
English (en)
Swedish (sv)
Other versions
FI117135B (fi
FI951132A0 (fi
Inventor
Eugen Uhlmann
Gerhard Breipohl
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of FI951132A0 publication Critical patent/FI951132A0/fi
Publication of FI951132L publication Critical patent/FI951132L/fi
Application granted granted Critical
Publication of FI117135B publication Critical patent/FI117135B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polyamides (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI951132A 1994-03-14 1995-03-10 Polyamidi-oligonukleotidijohdoksia, niiden valmistus ja niiden käyttö FI117135B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4408528A DE4408528A1 (de) 1994-03-14 1994-03-14 Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
DE4408528 1994-03-14

Publications (3)

Publication Number Publication Date
FI951132A0 FI951132A0 (fi) 1995-03-10
FI951132L true FI951132L (fi) 1995-09-15
FI117135B FI117135B (fi) 2006-06-30

Family

ID=6512694

Family Applications (2)

Application Number Title Priority Date Filing Date
FI951132A FI117135B (fi) 1994-03-14 1995-03-10 Polyamidi-oligonukleotidijohdoksia, niiden valmistus ja niiden käyttö
FI20051072A FI117939B (fi) 1994-03-14 2005-10-24 Polyamidi-oligonukleotidijohdoksia, niiden valmistus ja niiden käyttö

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20051072A FI117939B (fi) 1994-03-14 2005-10-24 Polyamidi-oligonukleotidijohdoksia, niiden valmistus ja niiden käyttö

Country Status (14)

Country Link
EP (2) EP1113021B1 (fi)
JP (1) JP4620810B2 (fi)
KR (1) KR100416864B1 (fi)
CN (1) CN100379756C (fi)
AT (2) ATE220070T1 (fi)
AU (1) AU698210B2 (fi)
CA (1) CA2144475C (fi)
DE (3) DE4408528A1 (fi)
DK (2) DK0672677T3 (fi)
ES (2) ES2179080T3 (fi)
FI (2) FI117135B (fi)
HK (2) HK1012003A1 (fi)
NO (1) NO314664B1 (fi)
PT (2) PT672677E (fi)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003542A1 (en) * 1996-07-24 1998-01-29 Buchardt, Dorte Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US6710164B1 (en) 1993-11-22 2004-03-23 Peter E. Nielsen Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US6150510A (en) 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
DE4438918A1 (de) * 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
PT739898E (pt) * 1995-03-13 2002-03-28 Aventis Pharma Gmbh Mono-esteres de acidos fosfonucleicos processo para a sua preparacao e sua utilizacao
DE19532553A1 (de) * 1995-09-04 1997-03-06 Hoechst Ag Verfahren zur Herstellung substituierter N-Ethyl-Glycinderivate
GB2324534B (en) * 1996-01-06 2000-05-10 Danbiosyst Uk Composition for delivery of nucleic acid to a cell
ES2221942T3 (es) * 1996-05-24 2005-01-16 Aventis Pharma Deutschland Gmbh Reactivo y metodo para inhibir la expresion de n-ras.
IL127244A (en) * 1996-05-31 2005-11-20 Allelix Neuroscience Inc Substituted amines, methods of their preparation and pharmaceutical compositions containing them
US6191165B1 (en) 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
DE19637339A1 (de) * 1996-09-13 1998-03-19 Hoechst Ag Verfahren zur Amplifikation von Nukleinsäuren
DE69829760T3 (de) 1997-09-12 2016-04-14 Exiqon A/S Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
WO1999034014A2 (en) * 1997-12-23 1999-07-08 Roche Diagnostics Gmbh A method for the determination of a nucleic acid
US5952202A (en) * 1998-03-26 1999-09-14 The Perkin Elmer Corporation Methods using exogenous, internal controls and analogue blocks during nucleic acid amplification
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
US6316230B1 (en) * 1999-08-13 2001-11-13 Applera Corporation Polymerase extension at 3′ terminus of PNA-DNA chimera
US7205105B2 (en) 1999-12-08 2007-04-17 Epoch Biosciences, Inc. Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for PCR analysis
DE10019135A1 (de) 2000-04-18 2001-10-31 Aventis Pharma Gmbh Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung
US7348146B2 (en) 2003-10-02 2008-03-25 Epoch Biosciences, Inc. Single nucleotide polymorphism analysis of highly polymorphic target sequences
WO2005043127A2 (en) 2003-10-28 2005-05-12 Epoch Biosciences, Inc. Fluorescent probes for dna detection by hybridization with improved sensitivity and low background
DE102006034319A1 (de) * 2006-07-21 2008-01-31 Ugichem Gmbh Chirale mit Phosponsäurester- oder Phosphonsäure- substituierte Verbindungen
EP2781523A1 (en) 2013-03-18 2014-09-24 Miltenyi Biotec GmbH Lipophilic oligonucleotide analogs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383803B1 (en) * 1987-10-28 2000-05-03 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates
WO1993024511A1 (en) * 1992-05-29 1993-12-09 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
IL104461A (en) * 1992-01-22 2001-05-20 Hoechst Ag Oligonucleotide analogs, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DE59510252D1 (de) 2002-08-08
ES2179080T3 (es) 2003-01-16
ATE335760T1 (de) 2006-09-15
JP4620810B2 (ja) 2011-01-26
JPH07278179A (ja) 1995-10-24
HK1038568A1 (en) 2002-03-22
NO314664B1 (no) 2003-04-28
EP1113021A2 (de) 2001-07-04
FI20051072L (fi) 2005-10-24
EP0672677A2 (de) 1995-09-20
EP0672677B1 (de) 2002-07-03
NO950955D0 (no) 1995-03-13
EP0672677A3 (de) 1996-01-17
PT672677E (pt) 2002-11-29
DE59511061D1 (de) 2006-09-21
ATE220070T1 (de) 2002-07-15
DK0672677T3 (da) 2002-10-28
HK1012003A1 (en) 1999-07-23
CN100379756C (zh) 2008-04-09
FI117939B (fi) 2007-04-30
AU1479895A (en) 1995-09-21
AU698210B2 (en) 1998-10-29
EP1113021A3 (de) 2001-07-11
KR950032265A (ko) 1995-12-20
CA2144475C (en) 2010-06-08
CA2144475A1 (en) 1995-09-15
DK1113021T3 (da) 2006-12-11
DE4408528A1 (de) 1995-09-28
PT1113021E (pt) 2006-12-29
EP1113021B1 (de) 2006-08-09
CN1112126A (zh) 1995-11-22
KR100416864B1 (ko) 2006-01-27
FI117135B (fi) 2006-06-30
NO950955L (no) 1995-09-15
ES2269239T3 (es) 2007-04-01
FI951132A0 (fi) 1995-03-10

Similar Documents

Publication Publication Date Title
FI955235L (fi) Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö
FI951132L (fi) Polyamidi-oligonukleotidijohdoksia, niiden valmistus ja niiden käyttö
NL300295I2 (nl) 3,3-diarylpropylaminen, de toepassing en bereidinghiervan
FI955913A (fi) Uudet erytromysiinijohdannaiset, menetelmät niiden valmistamiseksi ja niiden käyttö lääkkeinä
FI952359L (fi) Metalloseenikatalyyttisysteemit, niiden valmistaminen ja käyttö
FI964311L (fi) Bifunktionaalinen proteiini, valmistus ja käyttö
EE04151B1 (et) Atsüülpiperasinüülpürimidiinide derivaadid, nendevalmistamine ja kasutamine ravimitena
EP0710667A3 (de) Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
EE03482B1 (et) Kinasoliiniderivaadid, nende valmistamismeetod ja kasutamine
FI961457L (fi) Uusi kompleksiyhdiste, sen valmistus ja käyttö
CY2013003I1 (el) Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
EE05000B1 (et) 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
EE200000621A (et) Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine
FI951817L (fi) Orgonaluminoksituote, sen valmistus ja käyttö
EE9600172A (et) Puriin-6-ooni derivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja ravimid
FI950458L (fi) N-(3-aminopropyyli)-N-fenyyli-5,6,7,8-tetrahydronaftalen-2-karboksamidijohdannaiset, niiden valmistus ja terapeuttinen käyttö
EE9700288A (et) Asatsükloalkaani derivaadid, nende valmistamine ja kasutamine ravis
EE9800145A (et) Fenüülamidiini derivaadid, meetodid nende valmistamiseks ja nende kasutamine arstimitena
EE9900218A (et) 1,4-diasabitsüklo[2.2.2]okt-2-üülmetüülbensoaadi derivaadid, nende valmistamine ja kasutamine raviks
EE04317B1 (et) 4-okso-3,5-dihüdro-4H-püridasino[4.5-b]indool-1-etaanamiidi derivaadid, nende valmistamine ja kasutamine raviks
FI954946L (fi) Kinoksaliinit, menetelmä niiden valmistamiseksi ja niiden käyttö
EE200000207A (et) 8-asabitsüklo[3.2.1]oktaan-3-metaanamiini derivaadid, nende valmistamine ja terapeutiline kasutamine
FI971317A (fi) Uusia heterosyklisiä, substituoituja imidatsolokinoksalinoneja, niiden valmistus ja käyttö
EE200000018A (et) 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117135

Country of ref document: FI

MM Patent lapsed